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ARTICLE
Epidemiology
Body mass index throughout adulthood, physical activity, and
risk of multiple myeloma: a prospective analysis in three large
cohorts
Catherine R. Marinac1,2, Brenda M. Birmann3, I-Min Lee2,4, Bernard A. Rosner3, Mary K. Townsend5, Edward Giovannucci2,3,6,
Timothy R. Rebbeck1,2, Julie E. Buring2,4 and Graham A. Colditz2,7
BACKGROUND: Obesity is the only known modiﬁable multiple myeloma (MM) risk factor. However, the inﬂuence of obesity in
earlier or later adulthood and the role of other energy balance correlates in MM development are unclear.
METHODS: We leveraged repeatedly updated data from the Nurses’ Health Study, Health Professionals Follow-up Study, and
Women’s Health Study cohorts to further explore energy balance measures in MM etiology. Exposures derived from questionnaires
included young adult body mass index (BMI), cumulative average BMI, BMI change since young adulthood, and cumulative average
physical activity and walking. We assessed MM risk related to those variables with Cox proportional hazard models.
RESULTS:We observed 575 incident MM cases in over ﬁve million person-years of follow-up across the cohorts. In pooled analyses,
MM risk increased 17% per 5 kg/m2 increase in cumulative average BMI (95% conﬁdence interval (CI): 1.05, 1.29) and 28% per 5 kg/
m2 increase in young adult BMI (CI: 1.12, 1.47); adjustment for BMI change since young adulthood did not affect either association.
BMI change since young adulthood and cumulative average physical activity and walking were not signiﬁcantly associated with MM
risk.
CONCLUSIONS: These ﬁndings suggest that a high BMI in early and later adulthood are risk factors for MM.
British Journal of Cancer (2018) 118:1013–1019; https://doi.org/10.1038/s41416-018-0010-4
INTRODUCTION
Multiple myeloma (MM) is an incurable malignancy of plasma
cells, characterised by high levels of a monoclonal (“M”) protein in
peripheral blood and/or urine, bone marrow plasmacytosis and
clinical signs of organ damage.1 MM is preceded by an
asymptomatic premalignant condition known as monoclonal
gammopathy of undetermined signiﬁcance (MGUS),2, 3 and
individuals with MGUS have a risk of progression to MM of
~1–2% per year.4 MM is expected to account for >32,800 new
cancer diagnoses and >12,500 cancer deaths in the United States
(US) in 2017.5 Five-year relative survival has improved by more
than 15 percentage points since the year 2000 due to therapeutic
advancements;6–8 nonetheless it remains low at 52.7%.9 Alto-
gether, these data underscore the urgency of identifying
modiﬁable risk factors for disease incidence, which may be used
to inform prevention efforts.
Most established risk factors, including older age, male sex,
African ancestry, and family history of haematologic malig-
nancy, are not modiﬁable. An exception is obesity, which has
demonstrated a positive association with MM risk in
epidemiologic studies.10–12 Indeed, the strength and consis-
tency of the evidence supporting a positive association of
body mass index (BMI) with MM led an expert panel convened
by the International Agency for Research on Cancer (IARC) to
conclude in 2016 that a preventative relationship has been
established between “the absence of excess body fatness” and
MM.13
In light of the established association of obesity with MM,
clariﬁcation is warranted for other aspects of the relationship, such
as whether BMI in both earlier and later life are important. Several
published studies suggest that both younger and usual adult BMI
are positively associated with MM risk,10, 14 including a recent
pooled case–control study by the International Multiple Myeloma
Consortium (IMMC) with data on both younger and usual adult
BMI for 1164 cases and 3629 controls.10 Nonetheless, other
prospective studies did not observe associations with MM for
younger adult BMI,15, 16 including an analysis among 121,216 (n =
111 MM cases) women enrolled in the California Teachers Study.16
It is also unclear whether BMI change or physical activity also
inﬂuences the risk of MM. The IARC consensus report could not
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address these questions because the existing evidence is limited
(i.e., examined in few and/or under-powered studies) and
inconclusive. We undertook the present analysis in the Nurses’
Health Study (NHS), Health Professionals Follow-up Study (HPFS)
and Women’s Health Study (WHS) cohorts, with a pooled total of
575 cases of MM and 5,042,395 person-years of follow-up, to
elucidate these additional questions and better inform the
translation of the current knowledge on obesity to strategies to
diminish MM risk. This analysis updates and substantially expands
an early report on simple updated (“current”) BMI and cumulative
average hours/week of physical activity and MM risk in the NHS
and HPFS.17 The prior study included 10 fewer years of follow up
and only 215 MM cases, and did not include data from WHS




The NHS was established in 1976 with 121,700 female U.S.
registered nurses ages 30–55 years who completed the
enrollment questionnaire.18 The HPFS enrolled 51,529 U.S.
licensed male health professionals ages 40–75 years in 1986.
Participants in both cohorts have returned follow-up ques-
tionnaires biennially since enrollment to update lifestyle and
disease history information (http://nurseshealthstudy.org/
participants/questionnaires, https://sites.sph.harvard.edu/hpfs/
hpfs-questionnaires/). The WHS originally enrolled 39,876
healthy U.S. female health professionals ages 45 years and
over in 1992 for a randomised trial of aspirin and vitamin E for
cardiovascular disease and cancer prevention.19 Since comple-
tion of the trial in 2004, women have been followed in an
observational study (http://whs.bwh.harvard.edu/). Participants
in WHS reported on medical history and lifestyle characteristics
at baseline and throughout follow-up by means of question-
naires. HPFS, NHS and WHS participants with a baseline history
of cancer other than non-melanoma skin cancer were excluded
from the present analyses, leaving a combined baseline total of
49,374 men and 153,260 women.
The protocols for all three cohorts and the present analysis were
approved by the Institutional Review Boards at Brigham and
Women’s Hospital and the Harvard T.H. Chan School of Public
Health. Informed consent was implied by return of the baseline
questionnaire (HPFS, NHS) or provided in writing (WHS).
Assessment of height, weight, and BMI
Participants in each cohort reported their current height and
weight on the baseline questionnaires and updated current
weight on each follow-up questionnaire. Of note, self-
reported and technician-measured weights (r = 0.97) were
highly correlated in a subsample of participants.20 Body mass
index (BMI) for a given follow-up period was calculated
as weight (kilograms) divided by height (meters) squared
(kg/m2).
Assessment of young adult BMI
HPFS participants reported their weight at age 21 in 1986
(baseline); women in NHS reported their weight at age 18 in 1980,
and WHS participants reported their minimum and maximum
weight between ages 18–30 years on the questionnaire adminis-
tered 24-months after baseline. Young adult BMI was calculated
using height at enrollment, and using weight at age 21 for HPFS
and weight at age 18 for NHS participants. In a similarly-designed
companion cohort of women ages 25–42, self-recalled weight at
age 18 was strongly correlated (r = 0.87) with measured weight in
medical records.21 In WHS, young adult BMI was approximated
using the average of the minimum and maximum weight
between the ages of 18 and 30.
Assessment of physical activity
Detailed information on recreational physical activity (walking,
running, jogging, bicycling, racquet sports, calisthenics/aerobics,
swimming, weight training etc.) during the past year was assessed
in each study by standardised questionnaires--beginning in 1986
in HPFS and NHS and at baseline in WHS, and typically updated
every 2–4 years during follow-up. To incorporate activity
frequency, duration, and intensity into a summary measure of
energy expenditure, we calculated total metabolic equivalent
(MET) hours of all activity and of walking per week.22 These
physical activity measures have also been validated in both men
and women.23, 24
Outcome ascertainment
The outcome of interest was ﬁrst primary diagnosis of MM, which
we identiﬁed primarily through self-report on the follow-up
questionnaires, with additional cases identiﬁed when conﬁrming
vital status. Deaths were identiﬁed by next-of-kin, the postal
service or routine searches of the National Death Index, which was
shown to be highly sensitive and speciﬁc in these cohorts.25, 26 To
conﬁrm cases, we sought written consent for medical record
review from the participant or from next of kin (if deceased);
trained personnel reviewed medical records to conﬁrm the
occurrence and date of MM diagnosis. When the original medical
records were unavailable, we sought to conﬁrm case diagnoses via
linkage to state tumour registries. Follow-up time was censored in
2012 for NHS and HPFS and in the third observational follow-up
period for WHS, which was in 2008.
Statistical analyses
Person-time was calculated from study enrollment to the earliest
among dates of diagnosis of MM, another cancer (except non-
melanoma skin cancer), death, or the end of follow-up. For
analyses of physical activity and walking in NHS, follow-up began
in 1986. The exposures of interest included cumulative average
BMI, young adult BMI, change in BMI since young adulthood,
cumulative average physical activity, and cumulative average
walking. We calculated cumulative average variables as the mean
of all available information from baseline through each new
follow-up cycle, to better reﬂect individuals’ long-term exposure
and diminish the inﬂuence of misclassiﬁcation in any given follow-
up cycle.27 Cumulative average BMI was categorised as <23 kg/m2,
23–<25 kg/m2, 25–<27.5, 27.5–<30 kg/m2, and ≥30 kg/m2, con-
sistent with World Health Organization (WHO) categories28 except
that the usual “normal BMI” category of <25 kg/m2 group, and
“overweight BMI” category of 25–<30, which were sizable in these
cohorts, were split to permit a ﬁner assessment of dose-response
and to mirror the previously published study of BMI and MM risk
in NHS and HPFS.17, 29 Due to limited reports of obesity in young
adulthood, we modeled only three categories of young adult BMI
(<23 kg/m2, 23–<25 kg/m2, ≥25 kg/m2). Furthermore, BMIs con-
sidered underweight (<18.5 kg/m2) were uncommon and thus
excluded from all models that included younger or usual adult
(i.e., cumulative average) BMI. Change in BMI since young
adulthood (<0 kg/m2, 0–1.5 kg/m2, >1.5–3 kg/m2, >3 kg/m2) was
modeled with simple updates at each follow-up cycle. Cumulative
average physical activity was categorised as 0–<9, 9–<18, 18–<27,
≥27 MET-hours/week and cumulative average walking as 0–<3, 3–
<9, 9–<18, and ≥18 MET-hours/week. We also categorised physical
activity according to adherence to the World Cancer Research
Fund and American Institute for Cancer Research (WCRF/AICR)
joint physical activity recommendations, which we operationalised
as ≥210min per week.30 Finally, for comparison with correspond-
ing BMI variables, we also examined height, current weight, young
adult weight and change in weight since young adulthood in
relation to MM risk. We categorised height and (biennially
updated) weight variables in quartiles deﬁned in non-cases and
calculated updated change in weight since young adulthood (≤5,
Energy balance throughout adulthood and multiple myeloma














>5–10, >10–20, >20 kg). To test for linear trend, we further
examined each exposure as a continuous variable, speciﬁcally in 5
kg/m2 increments of cumulative average and young adult BMI and
change in BMI; in 5 kg increments for weight and weight change
variables; and in 10 MET-hour/week increments for the physical
activity variables. A one-cycle carry forward rule was applied to
variables to minimise missing data.
We examined interrelationships between young adult and adult
BMI variables with Spearman correlations. In separate Cox
proportional hazards models stratiﬁed by age (months) and
calendar period of follow-up, we calculated hazards ratios (HRs)
and 95% conﬁdence intervals (CI) for the association of a given
energy balance exposure category or continuous measure with
the risk of MM. To avoid potential collinearity when evaluating
whether young adult and usual adult BMI associations with MM
were independent of each other, we ran additional models of
each BMI variable with adjustment for change in BMI since young
adulthood; we also examined interactions between young adult
and usual adult BMI in a model that included both main effects
and a cross-product term, and examined joint associations of
young adult and cumulative average BMI. For consistency across
modeling strategies, and to examine whether associations
observed were independent of BMI earlier in life, models of
change in BMI since young adulthood were also run with and
without adjustment for young adult BMI. Models of cumulative
average physical activity and walking were run with and without
adjustment for cumulative average BMI; and all models of weight
and weight change additionally controlled for height.
Statistical outlier values were identiﬁed using the Rosner
extreme studentised deviate method,31 and all main models were
re-run without exposure outlier values as a sensitivity analysis. To
assess the potential inﬂuence of weight loss due to subclinical
MM, we also implemented a two-cycle (i.e., 4-year) exposure lag
and examined the lagged exposures in sensitivity analyses that
utilised a similar series of Cox models to those previously
described. Tests of interactions between the exposure of interest
and the (log-)time scale veriﬁed the proportional hazards
assumption in all main models. After pooling NHS and WHS data
by random-effects meta-analysis, ﬁnal models were run separately
by sex, and a random-effects meta-analysis was used to test for
heterogeneity by sex. We also derived “pooled” summary effect
estimates across the three cohorts using a random-effects meta-
analysis and tested for heterogeneity by cohort.
RESULTS
We conﬁrmed incident diagnoses of MM in 205 men (HPFS) and
370 women (325 NHS, 45 WHS). Participants were of similar
average age in all three cohorts and were predominantly White
(Table 1). Mean BMI ranged from 23.8–25.8 kg/m2 at baseline, and
from 21.3–23.0 kg/m2 in young adulthood.
We noted weak to moderate correlations for young adult and
later adult BMI variables in each cohort (Supplementary Table 1).
The correlations with young adult BMI were slightly stronger for
baseline BMI than for cumulative average BMI and somewhat
weaker for current BMI and change in BMI since young adulthood.
We observed a positive association with MM risk for both
cumulative average adult BMI and young adult BMI (Table 2).
Although the associations were somewhat stronger among men,
there was no statistically signiﬁcant heterogeneity in the sex- or
cohort-speciﬁc effect estimates (all p-values for heterogeneity
≥0.20 and ≥0.42, respectively), so we focus herein on the pooled
(e.g., meta-analysed) results across all cohorts. Accordingly, in
pooled analyses, each 5 kg/m2 increase in cumulative average
adult BMI was associated with a statistically signiﬁcant 17%
increased risk of MM (HR: 1.17; 95% CI: 1.05, 1.29). Adjustment for
change in BMI since young adulthood had only minimal inﬂuence
(Table 2). MM risk also increased by nearly 30% per 5 kg/m2
increase in young adult BMI (HR: 1.28; 95% CI: 1.12, 1.47), with no
appreciable effect of adjustment for change in BMI since young
adulthood. We did not see evidence of statistical interaction
between BMI in young adulthood and usual adult BMI (cohort-
speciﬁc P-values for interaction all ≥0.32), or trends across joint
categories of cumulative average and young adult BMI (Supple-
ment Table 2). Change in BMI since young adulthood was
suggestively but not signiﬁcantly associated with MM risk (p =
0.10), with adjustment for young adult BMI.
Models of weight in adulthood, young adulthood, and weight
change were directionally similar to the models of BMI described
above (and P-values for heterogeneity by sex and cohort were all
≥0.22 and ≥0.39, respectively), although the HR for weight change
since young adulthood reached statistical signiﬁcance (Supple-
ment Table 3). Each 5 kg increase in weight change since young
adulthood was associated with a signiﬁcant 4% increased risk of
developing MM (pooled HR: 1.04; 95% CI: 1.00, 1.08; P = 0.03) when
adjusted for height and young adult weight. We did not observe
statistically signiﬁcant associations with MM risk for adult height
(Supplement Table 3), nor did we observe statistically signiﬁcant
associations with MM risk for any physical activity variables
(Table 3) or evidence of interaction of a physical activity variable
with BMI in relation to MM risk (cohort-speciﬁc P-values for
interaction all ≥0.40). Sensitivity analyses conﬁrmed that the
outlier records (N = 2196 for cumulative average BMI; N = 3366 for
young adult BMI; N = 9160 for physical activity; N = 6935 for
walking) and a 4-year exposure lag did not inﬂuence the main
ﬁndings.
DISCUSSION
In this analysis of data from three large prospective cohorts, a
higher BMI in both later adulthood and young adulthood was
associated with a similarly increased risk of MM. This association
did not signiﬁcantly differ by gender but was nonetheless slightly
stronger in men. MM risk was signiﬁcantly positively associated
with weight change and suggestive of a positive association for
Table 1. Characteristics of the Health Professionals Follow-Up Study







Age at enrollment, years 54.50 (9.8) 48.82 (7.2) 54.35 (6.9)
Age at end of follow-up,
years
73.63 (7.9) 75.29 (6.9) 67.66 (6.8)
Race
White, % 91 97 94
Black, % 1 2 2
Asian, % 2 1 1
Other/miss, % 7 0 2
Body mass index, kg/m² 25.54 (3.4) 23.76 (4.2) 25.82 (5.0)
Young adult body mass
index, kg/m²
23.02 (3.0) 21.34 (3.0) 21.87 (3.1)
Change in BMI since
young adulthood, kg/m²
2.52 (2.9) 2.39 (3.6) 3.92 (3.8)
Activity, MET-h/weekb 18.75 (26.3) 14.07 (21.0) 14.58 (18.3)
Walking, MET-h/weekc 8.30 (13.6) 6.53 (9.4) 7.28 (7.2)
Values of polytomous variables may not sum to 100% due to rounding
aValues are mean (SD) and ascertained at baseline unless otherwise noted
bMetabolic equivalent hours per week from recreational and leisure time
activities
cMetabolic equivalent hours per week from recreational and leisure time
activities (walking only)
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change in BMI since young adulthood. In contrast, we did not
observe statistically signiﬁcant associations of cumulative average
physical activity or walking with MM risk.
In addition to supporting the strong evidence base for a causal
association between obesity and MM risk,13 the current study
addresses important knowledge gaps surrounding the importance
of BMI in earlier and later life for MM risk, a question investigated
in only a few studies. An analysis in the IMMC (1164 cases and
3629 controls with both younger and usual adult data) reported a
strong statistical interaction between younger and usual adult
BMI, with joint models indicating that MM risk was strongest
among individuals who were obese at both times, compared to
those whose BMI was normal at both times.10 Another joint
analysis conducted in an even larger prospective pooled study (20
cohorts, 1.5 million participants, 1388 MM deaths) observed the
highest MM mortality in women with a BMI≥ 30 both in young
adulthood and at baseline but no apparent joint effect in men.32 A
third prospective study reported similar positive associations of
MM risk with BMI in young adulthood and adulthood, with no
signiﬁcant interaction.14 The current study supports the latter
ﬁndings that BMI in younger and later adulthood are both
important for MM risk but did not replicate a statistical interaction
or trends across jointly classiﬁed categories of the two BMI
variables. However, it is notable that our case count accommo-
dated only two categories of each BMI variable in contrast to the
three ﬁner categories utilised in the IMMC analysis. Other
Table 2. BMI and the risk of incident multiple myeloma in men and women
Men Womena Pooledb
Cases Person-years HR (95% CI) Cases Person-years HR (95% CI) HR (95% CI)
Cumulative average BMI (kg/m2)
18.5–<23 kg/m2 20 143351 1.00 88 1218619 1.00 1.00
23–<25 kg/m2 54 238232 1.77 (1.04, 3.00) 61 669099 0.99 (0.61, 1.61) 1.19 (0.76, 1.88)
25–<27.5 kg/m2 52 265658 1.54 (0.90, 2.63) 56 571908 1.00 (0.65, 1.52) 1.14 (0.79, 1.65)
27.5–<30 kg/m2 22 126896 1.41 (0.76, 2.63) 53 333742 1.63 (1.16, 2.30) 1.44 (0.99, 2.08)
≥30 kg/m2 21 78753 2.27 (1.21, 4.28) 44 419586 1.14 (0.79, 1.65) 1.38 (0.83, 2.27)
HR per 5 kg/m2 1.25 (1.03, 1.52) 1.14 (1.01, 1.28) 1.17 (1.05, 1.29)
Ptrend 0.02 0.04 0.003
Cumulative average BMI (kg/m2) adjusted for change in BMI since young adulthood
18.5–<23 kg/m2 20 143351 1.00 88 1218619 1.00 1.00
23–<25 kg/m2 54 238232 1.82 (1.07, 3.09) 61 669099 1.02 (0.73, 1.43) 1.20 (0.75, 1.91)
25–<27.5 kg/m2 52 265658 1.65 (0.96, 2.85) 56 571908 0.98 (0.68, 1.41) 1.15 (0.77, 1.71)
27.5–<30 kg/m2 22 126896 1.57 (0.82, 3.00) 53 333742 1.55 (1.05, 2.29) 1.55 (1.11, 2.17)
≥30 kg/m2 21 78753 2.70 (1.35, 5.42) 44 419586 1.05 (0.66, 1.67) 1.48 (0.75, 2.90)
HR per 5 kg/m2 1.33 (1.09, 1.63) 1.13 (0.95, 1.33) 1.20 (1.06, 1.37)
Ptrend 0.006 0.16 0.005
Young adult BMI (kg/m2)
18.5–<23 kg/m2 69 403041 1.00 195 2153960 1.00 1.00
23–<25 kg/m2 49 230418 1.37 (0.94, 1.99) 39 396692 1.29 (0.59, 2.85) 1.27 (0.85, 1.89)
≥25 kg/m2 43 194116 1.49 (1.01, 2.19) 31 321214 1.11 (0.76, 1.62) 1.28 (0.97, 1.68)
HR per 5 kg/m2 1.39 (1.16, 1.67) 1.17 (0.95, 1.42) 1.28 (1.12, 1.47)
Ptrend 0.0004 0.13 0.0003
Young adult BMI adjusted for change in BMI since young adulthood
18.5–<23 kg/m2 69 403106 1.00 195 2153960 1.00 1.00
23–<25 kg/m2 49 230418 1.36 (0.93, 1.99) 39 396692 1.30 (0.60, 2.85) 1.27 (0.86, 1.89)
≥25 kg/m2 43 194116 1.48 (0.99, 2.21) 31 321214 1.14 (0.78, 1.68) 1.29 (0.98, 1.70)
HR per 5 kg/m2 1.42 (1.16, 1.73) 1.19 (0.97, 1.46) 1.30 (1.13, 1.50)
Ptrend 0.0006 0.09 0.0003
Change in BMI since young adulthood adjusted for young adult BMI
<0 kg/m2 23 109500 0.75 (0.43, 1.30) 30 393638 0.86 (0.52, 1.44) 0.81 (0.55, 1.17)
0–1.5 kg/m2 34 180818 1.00 32 423290 1.00 1.00
>1.5–3.0 kg/m2 36 181252 1.03 (0.64, 1.66) 38 462122 1.07 (0.66, 1.71) 1.05 (0.75, 1.47)
>3 kg/m2 68 356004 1.00 (0.65, 1.52) 165 1592817 1.10 (0.75, 1.62) 1.05 (0.79, 1.40)
HR per 5 kg/m2 1.06 (0.85, 1.32) 1.10 (0.98, 1.24) 1.09 (0.98, 1.21)
Ptrend 0.63 0.10 0.10
P-values of tests for heterogeneity by sex were all P≥ 0.20; P-values of tests for heterogeneity by cohort were all p≥ 0.42. Cohort-speciﬁc data are available
from the authors upon request
P-values for trend tests are derived from models with the exposure of interest modeled as a continuous variable
BMI body mass index
aData were pooled across the women-only cohorts using a random-effects meta-analysis
bData were pooled across the three cohorts using a random-effects meta-analysis
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published studies did not observe an association with MM for
younger adult BMI, including both case–control and prospective
studies limited by small numbers of MM cases and/or insufﬁcient
variability of young adult BMI to examine overweight or obese
values.15, 16, 33, 34 Collectively, the present and previous evidence
from the better-powered studies supports an inference that
weight control throughout adulthood may confer a beneﬁt of
reducing MM risk.
The IARC consensus report found compelling evidence that an
absence of excess body fatness in adulthood has a preventative
association with MM and asserted that mechanistic evidence
supports a causal cancer-preventive effect of weight loss on most
cancers.13 To date there is little data on MM risk in relation to
weight and/or BMI changes in adulthood, a question that may be
particularly relevant to MGUS patients given the lack of strategies
for minimising progression to malignancy.35 We are aware of one
previous study of weight change and MM. That study investigated
intentional weight loss and lymphohaematopoietic cancer risk
among women and found no association between net weight loss
since age 35 and MM risk, but had only 92 MM cases and thus had
limited statistical power to detect an association.15 Our ﬁndings,
which did not distinguish intentional from unintentional causes,
suggest that irrespective of starting BMI in young adulthood,
individuals who subsequently reduced their BMI or weight may
have had a decreased risk of MM. These data, combined with the
mechanistic evidence outlined in the IARC report, suggest that
weight loss may confer an added beneﬁt for MM prevention.
Studies are warranted to assess whether inclusion of young adult
and/or usual adult BMI would improve on current MGUS risk
stratiﬁcation, which is presently based on clinical parameters,36 as
well as to investigate the inﬂuence of weight loss on risk of
progression in adults with MGUS that have a high BMI.37
Additional evidence supports the plausibility of an obesity-
related increase in MM risk; speciﬁcally there is strong evidence
that physiological dysfunction of adipose tissue in obese persons
can promote MM pathogenesis. For example, adipose tissue in
obese individuals produces altered concentrations of pro-
inﬂammatory cytokines, lipid metabolites and lypolytic enzymes,
as well as altered adipokines and growth factors which can
inﬂuence the bone marrow microenvironment through systemic
signalling pathways.38–40 Collectively, along with obesity-
associated systemic changes, adipocyte-derived compounds may
Table 3. Physical activity, walking, and the risk of incident multiple myeloma in men and women
Men Womena Pooledb
Cases Person-years HR (95% CI) Cases Person-years HR (95% CI) HR (95% CI)
Cumulative average physical activity (MET-hours/week)
0–<9 MET-hrs 41 234922 1.00 134 1060299 1.00 1.00
9–<18 MET-hrs 40 208615 1.04 (0.67, 1.62) 86 666960 0.93 (0.70, 1.22) 0.96 (0.76, 1.21)
18–<27 MET-hrs 36 163131 1.17 (0.74, 1.85) 37 370575 0.70 (0.48, 1.00) 0.84 (0.55, 1.27)
≥27 MET-hrs 85 361618 1.33 (0.90, 1.96) 51 440449 0.85 (0.61, 1.18) 1.03 (0.73, 1.45)
HR per 10 MET-hrs 1.03 (0.97, 1.09) 0.94 (0.87, 1.02) 0.98 (0.92, 1.06)
Ptrend 0.42 0.11 0.66
Cumulative average physical activity (MET-hours/week), adjusted for cumulative average BMI
0–<9 MET-hrs 41 234922 1.00 134 1060299 1.00 1.00
9–<18 MET-hrs 40 208615 1.06 (0.68, 1.65) 86 666960 0.94 (0.72, 1.25) 0.98 (0.77, 1.23)
18–<27 MET-hrs 36 163131 1.20 (0.75, 1.90) 37 370575 0.72 (0.50, 1.04) 0.86 (0.56, 1.31)
≥27 MET-hrs 85 361618 1.40 (0.94, 2.07) 51 440449 0.88 (0.63, 1.23) 1.07 (0.76, 1.51)
HR per 10 MET-hrs 1.03 (0.97, 1.10) 0.95 (0.88, 1.02) 0.99 (0.93, 1.06)
Ptrend 0.27 0.18 0.84
Cumulative average walking (MET-hours/week)
0–<3 MET-hrs 47 279895 1.00 101 794822 1.00 1.00
3–<9 MET-hrs 69 329316 1.09 (0.75, 1.59) 126 948009 1.19 (0.55, 2.58) 1.04 (0.77, 1.41)
9–<18 MET-hrs 43 205327 0.93 (0.61, 1.43) 51 512466 1.14 (0.27, 4.85) 0.96 (0.51, 1.82)
≥18 MET-hrs 43 153730 1.22 (0.79, 1.86) 25 232783 0.79 (0.51, 1.23) 0.99 (0.72, 1.35)
HR per 10 MET-hrs 1.05 (0.92, 1.18) 0.93 (0.79, 1.09) 1.00 (0.91, 1.10)
Ptrend 0.48 0.35 0.97
Cumulative average walking (MET-hours/week), adjusted for cumulative average BMI
0–<3 MET-hrs 47 279895 1.00 101 794822 1.00 1.00
3–<9 MET-hrs 69 329316 1.11 (0.76, 1.62) 126 948009 1.20 (0.57, 2.51) 1.06 (0.79, 1.41)
9–<18 MET-hrs 43 205327 0.95 (0.62, 1.46) 51 512466 1.15 (0.28, 4.68) 0.98 (0.53, 1.80)
≥18 MET-hrs 43 153730 1.25 (0.81, 1.92) 25 232783 0.83 (0.53, 1.30) 1.03 (0.76, 1.40)
HR per 10 MET-hrs 1.05 (0.93, 1.19) 0.95 (0.81, 1.11) 1.01 (0.92, 1.12)
Ptrend 0.42 0.51 0.82
P-values of tests for heterogeneity by sex were all P≥ 0.08; P-values of tests for heterogeneity by cohort were all P≥ 0.19. Cohort-speciﬁc data are available
from the authors upon request
P-values for trend tests are derived from models with the exposure of interest modeled as a continuous variable.
BMI body mass index, hrs hours, MET Metabolic Equivalent
aData were pooled across the women-only cohorts using a random-effects meta-analysis
bData were pooled across the three cohorts using a random-effects meta-analysis
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serve as a fuel source for MM tumour cells and promote their
proliferation41 and reduce apoptosis.42, 43 In support of these
putative mechanisms linking obesity with MM development,
prospective epidemiologic studies have found associations with
future MM incidence for pre-diagnosis concentrations of serologic
biomarkers of obesity-related hormonal deregulation thought to
contribute to MM pathogenesis.44, 45
Physical activity and weight control have downstream effects
on many of the same metabolic systems postulated to contribute
to myelomagenesis,46 and animal data suggest that physical
activity may promote a bone marrow microenvironment that is
less conducive to tumour initiation.38, 47 Therefore, it is intriguing
that we did not observe an association between physical activity
and MM risk. This lack of association between physical activity and
MM risk is consistent with some (but not all) published reports
(reviewed in Jochem et al.48); most studies reported null or
suggestive inverse associations, including one large prospective
investigation which found no association between total or leisure-
time physical activity and MM risk, and no interaction of physical
activity with BMI.14 It is noteworthy, however, that to our
knowledge, all studies to date48 including the present study have
used self-report to characterise physical activity, an approach that
is prone to measurement error.
Limitations of the present study include the reliance on self-
reported measures of weight, height, and physical activity, which
although validated, may introduce random error and exposure
non-differential misclassiﬁcation. Also, the current study popula-
tions are homogeneous with respect to sociodemographic factors,
and therefore, caution must be applied when generalising our
ﬁndings to more diverse populations. The reliance on an average
of minimum and maximum weight from ages 18 to 30 years when
computing young adult BMI in the WHS may have introduced
misclassiﬁcation; however, the mean and SD for young adult BMI
and correlations among BMI variables were similar across the
cohorts, providing reassurance that any such misclassiﬁcation for
WHS participants was minimal. Finally, although there are few
established risk factors for MM, and we adjusted for age and
studied a predominantly white population, we were not able to
adjust for family history of haematologic malignancy or MGUS
status and cannot rule out residual confounding by these or other
unmeasured risk factors.
Strengths of the present analysis include the prospective design
with a relatively large sample size for a prospective study of MM.
In addition, the time-varying analysis of cumulative average
measures of adult BMI and physical activity levels diminished the
inﬂuence of misclassiﬁcation in any given follow-up cycle27 and
better captured individuals’ longer-term exposure. Furthermore,
the assessment of BMI in young adulthood permitted exploration
of the relevant timing of exposure in relation to MM risk.
In conclusion, our ﬁndings support the growing body of
literature demonstrating that a high BMI both early and later in
adulthood is associated with the risk of MM, and suggest that
maintaining a healthy body weight throughout life may be an
important component to a much-needed MM prevention strategy.
Further larger-scale studies aimed at clarifying the inﬂuence of
obesity timing and duration and at directly evaluating the role of
weight loss, ideally conducted in diverse prospective study
populations and in MGUS patients, will be important for
elaborating the role of weight maintenance in MM prevention
and for identifying high risk subgroups of patients that may
beneﬁt from weight loss.
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